Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

SHSE:603707 Stock Report

Market Cap: CN¥12.3b

Nanjing King-Friend Biochemical PharmaceuticalLtd Future Growth

Future criteria checks 2/6

Nanjing King-Friend Biochemical PharmaceuticalLtd is forecast to grow earnings and revenue by 24.6% and 16.1% per annum respectively. EPS is expected to grow by 23.7% per annum. Return on equity is forecast to be 11.4% in 3 years.

Key information

24.6%

Earnings growth rate

23.72%

EPS growth rate

Pharmaceuticals earnings growth17.9%
Revenue growth rate16.1%
Future return on equity11.36%
Analyst coverage

Low

Last updated08 Jun 2026

Recent future growth updates

Recent updates

Analysis Article • Apr 02

Some Shareholders Feeling Restless Over Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.'s (SHSE:603707) P/S Ratio

When you see that almost half of the companies in the Pharmaceuticals industry in China have price-to-sales ratios (or...
Analysis Article • Nov 27

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.'s (SHSE:603707) Popularity With Investors Is Under Threat From Overpricing

When you see that almost half of the companies in the Pharmaceuticals industry in China have price-to-sales ratios (or...
Analysis Article • Sep 30

Would Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Be Better Off With Less Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Aug 26

Investors Still Waiting For A Pull Back In Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707)

When you see that almost half of the companies in the Pharmaceuticals industry in China have price-to-sales ratios (or...
Analysis Article • Jun 26

Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Is Making Moderate Use Of Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • May 26

Getting In Cheap On Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707) Might Be Difficult

When you see that almost half of the companies in the Pharmaceuticals industry in China have price-to-sales ratios (or...

Earnings and Revenue Growth Forecasts

SHSE:603707 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20286,2431,169N/A5873
12/31/20275,346900N/A3333
12/31/20264,492728N/A5993
3/31/20264,0345861,1391,529N/A
12/31/20253,9915826231,183N/A
9/30/20253,7616508931,346N/A
6/30/20253,7617077171,305N/A
3/31/20253,8057347991,464N/A
12/31/20243,9248269941,501N/A
9/30/20243,877-4238531,503N/A
6/30/20243,770-4099911,595N/A
3/31/20243,628-3451,2691,698N/A
12/31/20233,931-1891,2001,619N/A
9/30/20234,0041,0238291,135N/A
6/30/20234,0411,101437727N/A
3/31/20233,8441,093142466N/A
12/31/20223,7131,091125595N/A
9/30/20223,7581,1224941,069N/A
6/30/20223,9111,1184621,035N/A
3/31/20223,9801,116376929N/A
12/31/20213,6871,059243684N/A
9/30/20213,5371,038-163242N/A
6/30/20213,270953-478-99N/A
3/31/20213,064875-820-469N/A
12/31/20202,915806-860-566N/A
9/30/20202,800770-869-761N/A
6/30/20202,689724-916-816N/A
3/31/20202,594660-850-744N/A
12/31/20192,470605N/A-841N/A
9/30/20192,224539N/A-553N/A
6/30/20192,027487N/A-285N/A
3/31/20191,875452N/A-184N/A
12/31/20181,700425N/A62N/A
9/30/20181,633425N/A-85N/A
6/30/20181,479418N/A-31N/A
3/31/20181,325380N/A-142N/A
12/31/20171,113314N/A-235N/A
9/30/2017915276N/A-268N/A
6/30/2017758193N/A-390N/A
3/31/2017668284N/AN/AN/A
12/31/2016582257N/A-287N/A
12/31/201546988N/A137N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603707's forecast earnings growth (24.6% per year) is above the savings rate (2.4%).

Earnings vs Market: 603707's earnings (24.6% per year) are forecast to grow slower than the CN market (27.5% per year).

High Growth Earnings: 603707's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 603707's revenue (16.1% per year) is forecast to grow slower than the CN market (16.8% per year).

High Growth Revenue: 603707's revenue (16.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 603707's Return on Equity is forecast to be low in 3 years time (11.4%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/04 19:05
End of Day Share Price 2026/07/03 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Zhu ChenCitic Securities Co., Ltd.
Wen DaiHuatai Research